Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2010 Aug 3:8:75.
doi: 10.1186/1479-5876-8-75.

Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions

Wan-Zhang Yang  1 , Yun Zhang, Fang Wu, Wei-Ping Min, Boris Minev, Min Zhang, Xiao-Ling Luo, Famela Ramos, Thomas E Ichim, Neil H Riordan, Xiang Hu
Affiliations
Clinical Trial

Safety evaluation of allogeneic umbilical cord blood mononuclear cell therapy for degenerative conditions

Wan-Zhang Yang et al. J Transl Med. .

Abstract

Background: The current paradigm for cord blood transplantation is that HLA matching and immune suppression are strictly required to prevent graft versus host disease (GVHD). Immunological arguments and historical examples have been made that the use of cord blood for non-hematopoietic activities such as growth factor production, stimulation of angiogenesis, and immune modulation may not require matching or immune suppression.

Methods: 114 patients suffering from non-hematopoietic degenerative conditions were treated with non-matched, allogeneic cord blood. Doses of 1-3 x 10(7) cord blood mononuclear cells per treatment, with 4-5 treatments both intrathecal and intravenously were performed. Adverse events and hematological, immunological, and biochemical parameters were analyzed for safety evaluation.

Results: No serious adverse effects were reported. Hematological, immunological, and biochemical parameters did not deviate from normal ranges as a result of therapy.

Conclusion: The current hematology-based paradigm of need for matching and immune suppression needs to be revisited when cord blood is used for non-hematopoietic regenerative purposes in immune competent recipients.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Javed MJ, Mead LE, Prater D, Bessler WK, Foster D, Case J, Goebel WS, Yoder MC, Haneline LS, Ingram DA. Endothelial colony forming cells and mesenchymal stem cells are enriched at different gestational ages in human umbilical cord blood. Pediatr Res. 2008;64:68–73. doi: 10.1203/PDR.0b013e31817445e9. - DOI - PubMed
    1. Hutton JF, Gargett T, Sadlon TJ, Bresatz S, Brown CY, Zola H, Shannon MF, D'Andrea RJ, Barry SC. Development of CD4+CD25+FoxP3+ regulatory T cells from cord blood hematopoietic progenitor cells. J Leukoc Biol. 2009;85:445–451. doi: 10.1189/jlb.1008620. - DOI - PubMed
    1. Gratwohl A, Baldomero H. Trends of hematopoietic stem cell transplantation in the third millennium. Curr Opin Hematol. 2009;16:420–426. doi: 10.1097/MOH.0b013e328330990f. - DOI - PubMed
    1. Haller MJ, Wasserfall CH, McGrail KM, Cintron M, Brusko TM, Wingard JR, Kelly SS, Shuster JJ, Atkinson MA, Schatz DA. Autologous umbilical cord blood transfusion in very young children with type 1 diabetes. Diabetes Care. 2009;32:2041–2046. doi: 10.2337/dc09-0967. - DOI - PMC - PubMed
    1. Harris DT. Non-haematological uses of cord blood stem cells. Br J Haematol. 2009;147:177–184. doi: 10.1111/j.1365-2141.2009.07767.x. - DOI - PubMed

Publication types